Ersodetug

Summary

Ersodetug (CHEMBL5314739) is a phase-3 clinical-stage antibody; indicated across 2 conditions including hypoglycemia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 2 conditions
• Clinical trials: 3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5314739
Name	Ersodetug
Type	Antibody
Max phase	3

Also known as: Ersodetug, Rz-358, Rz358, RZ358, XMetD, XOMA 247, XOMA 358, XOMA-247, XOMA-358, ERSODETUG

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
hypoglycemia	2	MONDO:0004946	HP:0001943

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE3	2
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06208215	PHASE3	ACTIVE_NOT_RECRUITING	RZ358 Treatment for Congenital Hyperinsulinism
NCT06881992	PHASE3	RECRUITING	A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
NCT07262970	Not specified	AVAILABLE	Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a Tumor

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).